PTEN-PI3K pathway alterations in advanced prostate cancer and clinical implications.
Atish D ChoudhuryPublished in: The Prostate (2022)
Further advances in selective pharmacologic inhibition of the PI3K/AKT/mTOR pathway in tumors, development of rational combinations, and appropriate biomarker selection to identify the appropriate tumor- and patient-specific vulnerabilities will be required to optimize clinical benefit from therapeutic targeting of this pathway.